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Methylation at the DNA sequence 5*-CpG is required for mouse development. MeCP2 and MBD1 (formerly
PCM1) are two known proteins that bind specifically to methylated DNA via a related amino acid motif and
that can repress transcription. We describe here three novel human and mouse proteins (MBD2, MBD3, and
MBD4) that contain the methyl-CpG binding domain. MBD2 and MBD4 bind specifically to methylated DNA
in vitro. Expression of MBD2 and MBD4 tagged with green fluorescent protein in mouse cells shows that both
proteins colocalize with foci of heavily methylated satellite DNA. Localization is disrupted in cells that have
greatly reduced levels of CpG methylation. MBD3 does not bind methylated DNA in vivo or in vitro. MBD1,
MBD2, MBD3, and MBD4 are expressed in somatic tissues, but MBD1 and MBD2 expression is reduced or
absent in embryonic stem cells which are known to be deficient in MeCP1 activity. The data demonstrate that
MBD2 and MBD4 bind specifically to methyl-CpG in vitro and in vivo and are therefore likely to be mediators
of the biological consequences of the methylation signal.
DNA methylation is the major modification of eukaryote
genomes. In vertebrates, this occurs predominantly at position
5 of cytosines when followed by guanosine (CpG). DNA meth-
ylation can repress transcription and for this reason has been
implicated in stable alterations of gene expression in develop-
ment (3). Whereas the genomes of certain invertebrates ap-
pear to contain “compartments” of either mostly methylated or
mostly unmethylated DNA (43), the somatic genomes of ver-
tebrates are globally methylated, with the exception of so-
called CpG islands (6). CpG islands are GC-rich regions of
DNA, stretching for an average of about 1 kb, which are
coincident with the promoters of approximately 60% of human
RNA polymerase II-transcribed genes (1). Methylation of
CpG islands and subsequent silencing of associated transcrip-
tion units have been found to occur in genes located on the
inactive X chromosome (39), genes silenced by genomic im-
printing (36, 38), and genes silenced in transformed cell lines
and tumors (2, 8, 16, 18, 40). DNA methylation is known to
play an essential role in mammalian development because
mice lacking a functional gene encoding the maintenance
DNA methyltransferase (DNMT) are developmentally re-
tarded and die at midgestation (29). In contrast to the situation
in somatic cells, undifferentiated embryonic stem (ES) cells
lacking a functional DNMT gene apparently grow normally
despite containing approximately 5% of the wild-type DNA
methylation level (25, 35).
One mechanism by which DNA methylation can cause tran-
scriptional repression is by directly interfering with the binding
of sequence-specific transcription factors to DNA. Some tran-
scription factors have been shown to be unable to bind to their
target sequences when methylated (14, 21). The observations
that DNA methylation is capable of repressing transcription at
some distance (12, 23) and that repression of transgenes only
occurs after chromatin assembly (11) are inconsistent with the
direct mechanism and indicate that a more indirect mechanism
also exists. Two proteins have been identified, MeCP1 and
MeCP2, which bind specifically to methylated DNA in any
sequence context (27, 30). Both are capable of inhibiting tran-
scription (9, 32). It is likely that MeCP1 and MeCP2 are im-
portant in interpreting the signal that methylation of DNA
represents.
MeCP2 consists of a single polypeptide that contains both a
methyl-CpG binding domain (MBD) and transcriptional re-
pression domain (TRD) (32, 33). MeCP2 is capable of binding
to a single symmetrically methylated CpG pair and was found
to bind to chromosomes at sites known to contain methylated
DNA (35). On mouse chromosomes, this is visualized as prom-
inent binding to the highly methylated major satellite located
just proximal to centromeres, whereas on human or rat chro-
mosomes which do not contain highly methylated satellite
DNAs, general chromosomal binding is observed (32). MeCP2
localization is disrupted in ES cells lacking a functional DNMT
gene, demonstrating that MeCP2 is a bona fide methyl-CpG
binding protein in vivo (35). Like DNMT-deficient ES cells,
MeCP2-deficient ES cells appear to grow normally in culture
but are not capable of supporting embryonic development
(42). In contrast to DNMT deficiency, however, MeCP2 defi-
ciency is compatible with somatic cell viability, and certain
imprinted genes known to be misexpressed in the absence of
DNMT (5, 28) are not misexpressed in MeCP2-deficient cells
(17a). These observations suggest that the effects of DNA
methylation are not solely dependent on MeCP2, as the DNA
methylation-dependent transcriptional silencing observed at
imprinted loci does not appear to rely upon its presence. The
known characteristics of MeCP2 point to it being responsible
for genomewide transcriptional repression or “transcriptional
noise reduction” (7). Its involvement in the repression of spe-
cific genes remains unproven.
In contrast to MeCP2, MeCP1 has been shown to require
.10 methyl-CpGs to bind DNA (30), making it more likely to
be involved in DNA methylation-mediated transcriptional re-
pression of specific genes. Indeed, Boyes and Bird have shown
that MeCP1 is capable of repressing transcription of densely
methylated promoters (9). Further, MeCP1 was found to be
capable of repressing transcription from sparsely methylated
promoters, though the interaction is weak and can be over-
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come by the presence of an enhancer (10). MeCP1 activity is
ubiquitous in somatic cells and tissues but is notably absent in
ES cells which are also tolerant of DNMT deficiency (30).
Thus, MeCP1 is likely to be important in the DNA methyla-
tion-mediated repression of genes in somatic cells.
MeCP1 is a large protein complex of 400 to 800 kDa. Cross
et al. (15) recently identified a component of MeCP1 by
searching the XREF database (4) for sequences homologous
to the MBD of MeCP2. A human expressed sequence tag
(EST) was identified and found to encode a novel protein
containing a MBD-like motif located at its N terminus. This
protein, called MBD1 (formerly PCM1), was shown to bind
methylated DNA via its MBD-like region and to repress tran-
scription from a methylated promoter in vitro. MBD1 is a
component of the MeCP1 protein complex. We now report the
identification of three novel MBD-containing proteins. We
show that two of these novel proteins specifically bind meth-
ylated DNA in vitro and colocalize with methylated sequences
in vivo and are thus candidates for mediators of the effects of
DNA methylation in mammalian cells.
MATERIALS AND METHODS
cDNA identification and cloning. Full-length human MeCP2 and the MBD
region of MBD1 protein sequences were used to search the XREF database
(http://www.ncbi.nlm.nih.gov/XREFdb) or dbEST directly via BLAST (NCBI
BLAST Server; http://www.ncbi.nlm.nih.gov/BLAST). The murine homologue of
MBD1 was not present in the EST database so degenerate primers designed
from the amino acid sequences of the cysteine-rich motifs of the human MBD1
gene (primer G235 [59-CARACNCARGARGAYTGYGG-39] and primer D355
[59-CCNCCRAAYTTRGGYTTRTC-39]; designed by M. Carr) were used to
amplify a portion of the murine cDNA. This PCR product was then used to
screen a mouse brain cDNA library (Stratagene), and full-length clones were
isolated and sequenced. Approximately 2 3 105 plaques were plated out and
lifted onto nitrocellulose filters. Filters were hybridized in Church buffer (7%
sodium dodecyl sulfate [SDS], 0.5M sodium phosphate [pH 7.2]) supplemented
with 15 mg of denatured salmon sperm DNA per ml at 68°C overnight and
washed to a final stringency of 0.1% SDS–0.1 3 SSC (13 SSC is 0.15 M NaCl
plus 0.015 M sodium citrate) at 65°C.
Mbd2 and Mbd3 were identified by database screening as ESTs (accession no.
Z31258 for Mbd2 and accession nos. W81894 and W91000 for Mbd3). The
corresponding cDNA clones (MMTEST693, 403236, and 420899, respectively)
were obtained and used to screen the mouse brain cDNA library. A number of
full-length clones were isolated and sequenced for both Mbd2 and Mbd3. Human
MBD2 and MBD3 sequences were identified by subsequent screening of the
dbEST database with full-length Mbd2 and Mbd3 sequences. No full-length
MBD2 or MBD3 IMAGE clones were identified in database screens so 59 rapid
amplification of cDNA ends (RACE) was used to obtain the 59 end of MBD3 by
the 59 RACE protocol of Boehringer Mannheim. To obtain the 59 end of MBD2,
a gridded cosmid library (Lawrence Livermore National Laboratories cosmid
library LL18NC02; provided by the United Kingdom Human Genome Mapping
Project Resource Centre [HGMP], Cambridge, England) was screened with a
PCR product corresponding to the 59 end of MBD2 intron 1 (PCR product of
primers 59-AAAATCTGGGCTAAGTGCTGG-39 and 59-ACGCCTTCCACAT
AAGATGC-39), using the hybridization conditions described above. Two inde-
pendent cosmids (clones AD15-O10 and AD17-O6) were identified and sub-
cloned, and the relevant regions were sequenced.
MBD4 was identified as an EST (AA149549). The corresponding clone
(588272) was sequenced and found to contain a long open reading frame. No
ESTs for Mbd4 were present in the database, so the human cDNA was used as
a probe against a mouse 129 genomic lambda library (a gift from A. J. H. Smith).
Hybridization conditions were as described above, but filters were washed to a
final stringency of 1% SDS–0.5 M NaCl–50 mM Tris (pH 8) at 65°C. Positive
clones were identified which, upon subcloning and sequencing, were found to
contain the Mbd4 gene. Genomic clones were used to screen a mouse brain
cDNA library which resulted in the identification of one partial cDNA containing
a short poly(A) tail. This cDNA was used as a probe on a gridded mouse cDNA
library (embryonic region cDNA library ER-IV, HGMP; 17), and another partial
cDNA clone which ends in a poly(A) at the same location was identified. The
full-length Mbd4 sequence was determined by sequencing of cDNAs and by
comparison of genomic sequence to that of the human MBD4 cDNA, followed
by verification by RT-PCR, 59 RACE, and sequencing of products.
All IMAGE consortium (LLNL) cDNA clones (26) described here were ob-
tained from the HGMP, except for clones 400458, 403236, and 420899, which
were obtained from Research Genetics; clone HIBAA05 (MBD3), which was
obtained from the American Type Culture Collection; and clone MMTEST (46),
which was obtained from Christer Ho¨o¨g, Stockholm, Sweden. Sequencing was
performed with an ABI Automated Sequencer 373A Stretch apparatus. Contig
construction, sequence analysis, and comparison was performed by using the
Lasergene DNA analysis software package (DNAStar).
Expression analysis. Total RNA was isolated from tissues of adult mice using
acid guanidinium thiocyanate-phenol-chloroform extraction (13). Ten or 20 mg
of total RNA was used per lane on Northern blots. Blots were hybridized in
Church buffer as described above. Blots were washed to a final stringency of
0.1% SDS–0.13 SSC at 68°C for all probes except Mbd4, which was washed to a
final stringency of 1% SDS–0.5 M NaCl–50 mM Tris (pH 8) at 65°C. Signal was
detected with a PhosphorImager (Molecular Dynamics). For reverse transcrip-
tion-PCR (RT-PCR) analysis, 5 mg of total RNA was reverse transcribed at 42°C
by Moloney murine leukemia virus reverse transcriptase for 2 h according to the
manufacturer’s instructions (Life Technologies). One microliter of the reverse
transcriptase reaction mixture was then subjected to 30 cycles of PCR.
Construction of expression vectors and protein expression. The coding se-
quences for all four genes were PCR amplified (Mbd1, 59-AAGCATCCATGG
CTGAGTCCTGGC-39 and 59-GGGAGGGCAGTAATAAGGCCAGTCA-39;
Mbd2, 59-GGGAAGACCATGGACTGCCCG-39 and 59-GCGGATCCTTACG
CCTCATCTCCCTC-39; Mbd3, 59-GGCGCCATGGAGCGGAAGAGGTG-39
and 59-TCCCCCGGCACTCGCTCTGGCTCCGG-39; Mbd4, 59-GCGCCATG
GAGAGCCCAAACCTTG-39 and 59-GCGGATCCAGGCAGCTTCAAGATA
G-39; MBD4, 59-CCTGCTCCATGGGCACGACTGGGCTG-39 and 59-GCGG
GATCCTGAGCTTGAAAGCTGCAG-39) using Pfu polymerase (Stratagene)
or Pwo polymerase (Boehringer Mannheim) according to the manufacturer’s
instructions and cloned into the bacterial expression vector pET6H (19). Re-
combinant proteins were expressed in Escherichia coli BL21(DE3)/pLysS as
described previously (15) and purified over a nickel agarose column (Ni21-NTA-
Superflow Agarose [Qiagen]). Extracts were loaded onto the column, washed in
a solution containing 60 mM imidazole, 250 mM NaCl, 20 mM Tris (pH 7.9),
10% glycerol, 0.1% Triton X-100, and 10 mM 2-mercaptoethanol, and eluted in
elution buffer (wash buffer containing 0.5 M imidazole). Proteins were further
purified by fractionation over Fractogel EMD SO3--650(M) (Merck). Proteins
partially purified on the nickel-agarose column were loaded onto the Fractogel
column, washed in a solution containing 250 mM NaCl, 50 mM HEPES (pH 7),
10% glycerol, 0.1% Triton X-100, and 10 mM 2-mercaptoethanol, and eluted in
the same buffer containing 1 M NaCl. All column wash and elution buffers were
supplemented with complete protease inhibitor tablets (Boehringer Mannheim).
Constructs producing MBD1-GFP, MBD4-GFP, and MeCP2-GFP were made
by PCR amplifying either cloned cDNAs (Mbd1) with Pfu polymerase as de-
scribed above or reverse-transcribed total ES cell RNA (Mbd4) or murine brain
RNA (Mecp2) with Pwo polymerase as described above, digesting the PCR
products with HindIII and KpnI or KpnI alone (Mecp2), and ligating into the
pCMXGFP mammalian expression vector. The MBD2-GFP construct was made
by cloning the coding sequences (NaeI-SspI fragment) of a full-length Mbd2
cDNA into the HindIII site of pCMXGFP. pCMXGFP was constructed by K.
Umesono by insertion of the green fluorescent protein (GFP) cDNA (37) into
Asp718-BamHI-cut pCMX vector (44). The GFP cDNA is under the control of
a cytomegalovirus promoter and both a polyomavirus enhancer and a simian
virus 40 enhancer. This version of GFP contains the following amino acid chang-
es: F64L, V163A, S175Q, I167T, and S65T. The GFP-MBD3 construct was made
by PCR amplifying an Mbd3 cDNA with Pfu polymerase, digesting with BglII and
SpeI, and ligating into the pCMXGFP2 mammalian expression vector. pC-
MXGFP2 was derived from pCMXGFP by mutating the stop codon for the GFP
from TGA to GGG by PCR mutagenesis. Primers used were as follows: for
Mbd1, 59-GCGGAAGCTTATGGCTGAGTCCTGGCAG-39 and 59-GCGGTA
CCCAAAACTTCCTCCTTCAACTGC-39; for Mbd3, 59-GCAGATCTATGGA
GCGGAAGAGGTGG-39 and 59-GCACTAGTACACTCGCTCTGGCTCC-39;
for Mbd4, 59-GCGAAGCTTATGGAGAGCCCAAACCTTG-39 and 59-GCGG
TACCAGGCAGCTCCAAGATAGAC-39; for MeCP2, 59-GCGGTACCATGG
TAGCTGGGATGTTAG-39 and 59-GCGGTACCGCTAACTCTCTCGGTCA
CG-39.
Band shifts. Band shift assays were performed essentially as described previ-
ously (15) except that binding reactions were carried out at room temperature for
30 min and contained 100 ng of sonicated E. coli DNA for MBD1, MBD2, and
MBD4 or 200 ng of E. coli DNA for MBD3. Complexes were electrophoresed
through 2% agarose gels or 6% polyacrylamide gels in 0.53 TBE (Tris-borate
EDTA) at 4°C. The GAM12 and GAC probes have been described previously
(27). The double-stranded Sm probe was made by A. Prokhortchouk et al. (37a).
The NB probe was made by excising a 125-bp NcoI-BamHI fragment from the
MBD1 cDNA clone 222390 (15). Doubly methylated and fully methylated NB
were made by methylation with HpaII and HhaI methylases or SssI methylase
(New England Biolabs), respectively. The 51 probe was a gift from J. Huntriss
and M. Monk (20). The MM1 and MM2 probes were designed by H.-H. Ng.
GAM12, GAM5, GAC, MeCG11, and CG11 probes have been described pre-
viously (27, 30).
Cell culture, transfection, and fluorescence imaging. L, HT1080, and CHO
cells were grown on coverslips in minimal essential medium alpha (Life Tech-
nologies) supplemented with either 10% (L cells) or 5% (HT1080 and CHO
cells) bovine calf serum (Hyclone). EFS2 cells were derived from an ES cell line
containing a randomly integrated b-geo transgene (42). Embryonic fibroblasts
were obtained from this line by injecting ES cells into blastocysts and selecting
resistant cells (500 mg of Geneticin per ml and 10% bovine calf serum in minimal
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essential medium alpha [Life Technologies]) from dissociated embryos in culture
(17b). ES cells were grown in Glasgow medium (Life Technologies) supple-
mented with 10% fetal calf serum (Globepharm), 13 nonessential amino acids
(Life Technologies), 1 mM sodium pyruvate, 50 mM 2-mercaptoethanol, and
soluble differentiation-inhibitory activity/leukemia-inhibitory factor (41) at 37°C
in a 5% CO2 atmosphere. Ten micrograms of each expression construct was
transfected at approximately 50% confluence by using Lipofectin or Lipo-
fectamine (Life Technologies) onto 2-cm2 coverslip of cells at 50% confluence
according to the manufacturer’s instructions. Approximately 36 h after transfec-
tion, cells were fixed in 4% paraformaldehyde in phosphate-buffered saline for 20
min at 37°C and then washed twice in phosphate-buffered saline. Coverslips were
mounted in Vectashield (Vector Laboratories) containing 1 mg of 49,6-diami-
dino-2-phenylindole (DAPI) per ml and visualized directly. Images were ob-
tained using a Zeiss epifluorescence microscope fitted with a charge-coupled
device camera (Photometrics) and controlled by a Macintosh computer running
the Quips mFISH software (Vysis Inc.).
Nucleotide sequence accession numbers. All sequences reported here are
available in Genbank under accession nos. AF072240 to AF072252. Human EST
contigs for MBD2, MBD3, and MBD4 can be found as entries Hs.25674,
Hs.107254, and Hs.35947, respectively, through the UniGene web page: http://
www.ncbi.nlm.nih.gov/Schuler/UniGene.
RESULTS
A family of MBD-containing proteins. We sought to identify
novel proteins containing a MBD-like motif by searching the
EST database. In addition to Mecp2 and MBD1, three other
genes (Mbd2, Mbd3, and Mbd4) were identified in humans and
mice encoding proteins containing putative MBDs. Assign-
ment of the initiator AUG codons for each gene was given to
the first in-frame ATG in each case. While this location is
conserved in the human and murine Mbd1, Mbd2, and Mbd3
genes, it is not conserved in human and murine Mbd4 genes. In
both the human and murine Mbd4 genes, the AUG codon at
which we propose translation initiates is the only in-frame
methionine codon N terminal to the MBD-like region. The first
in-frame start codons in the Mbd2 and MBD2 open reading
frames is within a CpG island, and the second is located 152
codons downstream, just upstream of the MBD. These two
potential initiator codons show 6 of 10 and 5 of 10 matches to
the Kozak consensus sequence for initiator codons, respec-
tively (24). Conceptual translation of the region between the
first two ATG codons produces a repetitive amino acid se-
quence due to the high G1C content of the underlying DNA.
At this point, we do not known which initiator methionine is
used in vivo, though the high degree of conservation between
the human and murine genes in this CpG island is consistent
with the first methionine being the true initiator methionine.
Alignment of the MBD-like regions from the murine MBD1
to MBD4 and MeCP2 proteins is shown in Fig. 1A. The MBD
protein family comprises two subgroups based upon the se-
quences of the putative MBDs (Fig. 1A). The MBD of MBD4
is most similar to that of MeCP2 in primary sequence, while
the MBDs of MBD1, MBD2, and MBD3 are more similar to
each other than to those of either MBD4 or MeCP2. The
MBDs within each protein appear to be related evolutionarily
based on the presence of an intron located at a conserved
position within all five genes (Fig. 1A).
With the exceptions of MBD2 and MBD3, sequence simi-
larity between the proteins is limited to the MBDs themselves.
MBD3 is highly similar to MBD2 over most of its length with
71.1% overall amino acid identity (Fig. 2), diverging only at the
extreme C terminus where MBD3 has 12 consecutive glutamic
acid residues encoded by an imperfect trinucleotide repeat.
FIG. 1. Comparison of MBD family proteins. (A) Amino acid alignment of the MBDs from murine MBD1, MBD2, MBD3, MBD4, and MeCP2 proteins. Amino
acids identical in three or more proteins are indicated by shading. The location of an intron present in all five genes is indicated. (B) Comparison of MBD protein
structure. Proteins are indicated as horizontal lines, and MBDs are shown as labeled white boxes. Two forms of MBD2 are shown corresponding to initiation of
translation at either the first (MBD2a) or second (MBD2b) methionine codons (see text). The cysteine-rich repeats of MBD1 are represented by two black boxes, and
the repression domain of MeCP2 is indicated as a stippled box. The glycine-arginine repeat in MBD2a and the C-terminal glutamic acid repeat of MBD3 are indicated
as horizontal lines beneath the respective proteins. Alternate splice events are indicated as diagonal lines above or below the line of the protein. Any novel translation
termination codons introduced in alternate splice events are indicated. The brain-specific splice of MBD1 and testis-specific splice of MBD2 are labeled B and T,
respectively. Predicted molecular masses (in kilodaltons) and isoelectric points of each protein are also listed. The isoelectric point of the MBD3 protein is given both
for the full-length protein and, in parentheses, for the protein excluding the glutamic acid repeat. aa, amino acids.
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This characteristic is also conserved in the rat and human
MBD3 proteins, although the acidic tail of the latter homo-
logue is slightly longer and contains aspartic acid residues as
well as glutamic acid residues. MBD2 and MBD3 show high
conservation between human and murine genes (97.6 and
93.8% amino acid identity, respectively), whereas the human
and murine homologues of MBD1 and MBD4 are less well
conserved (70.9 and 65.5% amino acid identity, respectively
[data not shown but all sequences are available in GenBank]).
Searches of the protein databases revealed no significant
matches for MBD1, MBD2, or MBD3 outside of the MBDs
and the CxxCxxC motifs of MBD1 (15). Searches with the
MBD4 protein sequence produced a series of low-scoring hits
to bacterial DNA repair enzymes (data not shown).
Cloning of the murine Mbd1 gene revealed the presence of
three exons with a potential to encode cysteine-rich domains
(CxxCxxC [Fig. 1B]), whereas the human gene was reported to
encode only two of these domains (15). RT-PCR analysis of
various murine tissues detected an alternately spliced RNA
form in which the exon encoding the third CxxCxxC motif is
excluded from the mature message (Fig. 1B). Further investi-
gation of ESTs present in the databases allowed us to identify
human MBD1 ESTs in which an exon encoding a third Cxx-
CxxC motif is present (accession nos. U55972 and R14016).
Whereas the 39 CxxCxxC-encoding exon is alternately spliced
in mice, the 59-most CxxCxxC-encoding exon is alternately
spliced in the human gene. Thus, both the human and murine
Mbd1 genes can generate proteins containing two or three such
motifs depending upon alternate splicing. An additional alter-
nate splicing event was also detected in cDNA derived from
mouse brain in which the third exon (encoding the C-terminal
half of the MBD) is removed (Fig. 1B, splice labeled B). This
splicing event does not maintain the correct reading frame in
subsequent exons, and any resulting RNAs would not be ex-
pected to encode a functional protein. A third alternate splice
would result in the replacement of the C-terminal 29 amino
acids with an alternate 44-amino-acid C-terminal tail. This
splice variant was found in cDNAs from both brain and em-
bryonic cDNA libraries (this study and IMAGE clone 400458,
accession no. W77338) but was not detectable by RT-PCR and
is therefore predicted to occur with very low frequency.
A number of cDNAs isolated for the Mbd3 gene contain an
in-frame deletion of the first exon which would result in a
transcript lacking the coding sequence for the N-terminal half
of the MBD (Fig. 1B). This appears to be due to the use of an
alternate splice donor site within the first exon. This protein
would be only slightly smaller than the full-length protein, but
the MBD would be destroyed. Both spliced and unspliced
forms of the message are readily detectable in many somatic
tissues by RT-PCR, indicating that the shorter message makes
up a significant fraction of total Mbd3 message (Fig. 1B and
data not shown). The Mbd2 gene is also capable of using
alternate splicing to produce potentially nonsense transcripts:
a rare, larger form of the transcript includes an alternate fourth
exon (49 [Fig. 1B]) which contains an in-frame stop codon. The
testis-specific form seen in Fig. 3B results from the inclusion of
an alternate third exon which again results in early termination
of the reading frame and truncation of the message (T [Fig.
1B]). This testis-specific exon was found in both the human and
murine genes, though the level of sequence conservation in this
exon is much lower than that seen for the rest of the coding
region. Evidence of alternate splicing was also found for the
human and murine Mbd4 transcripts. None of the identified
alternately spliced forms affect the coding sequence of the
MBD-like region, though one form of the human message
found in the EST database would result in a truncated protein
lacking the C-terminal 42 amino acids which are completely
conserved between the human and murine genes. The signifi-
cance of these alternately spliced variants is not known but may
reflect a common method for the regulation of the MBD pro-
tein family members.
Expression of Mbd genes. MeCP1 activity has been detected
in numerous somatic cell types but is notably absent in ES cells
and germ cells (30). In order to determine the expression
pattern of the Mbd genes, the corresponding cDNA clones
were hybridized to Northern blots containing RNA from var-
ious murine tissues including testis and ES cells (Fig. 3). The
Mbd genes were expressed in all somatic tissues tested. No
Mbd1 transcripts were detectable in ES cells, consistent with
the absence of MeCP1 activity in these cells. Similarly, Mbd2
transcript levels were significantly reduced in ES cells, while an
alternately spliced transcript of reduced size is detected in
testis (see above). DNA methylation is known to be dispens-
able in ES cells (25) so it would not be surprising for methyl-
CpG binding proteins to be reduced or absent in this cell type.
Mbd2 expression was detected as a doublet RNA band in
somatic tissues, which may reflect alternate polyadenylation
site usage. Mbd3 transcripts were detectable in all tissues
tested, including testis and ES cells. Mbd4 expression was un-
detectable on Northern blots except at very low levels in ES
cells, though expression was detectable in all tissues by RT-
PCR (data not shown). Expression of MBD4 was detectable in
FIG. 2. Amino acid alignment of murine MBD2 and MBD3. Identical residues are indicated with a vertical line between the sequences; homologous residues are
indicated with a colon, and similar residues are indicated with a period. Boxed amino acids correspond to the MBD. The glutamic acid repeat of MBD3 is represented
by (E12). Amino acid numbering for MBD2 begins from the upstream initiator methionine (see MBD2a in Fig. 1B).
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RNA from numerous human somatic tissues as well as ovary
and testis (data not shown).
MBD proteins bind methylated DNA in vitro. The MBD
protein family members were identified due to the presence in
each of a MBD-like region. We tested recombinant forms of
each protein for the ability to bind to methylated and unmeth-
ylated DNA probes in a gel retardation assay. As shown in Fig.
4, MBD1, MBD2, and MBD4 all produce a specific complex
with a methylated probe but not with the unmethylated version
of the same probe (Fig. 4, compare lanes 3 and 4, 7 and 8, and
15 and 16). The bipartite shift observed with MBD1 is likely
due to the presence of a 36-kDa degradation product within
the recombinant MBD1 preparation, as was also seen with
the human protein (15). The methyl-CpG-specific complexes
formed by MBD1, MBD2, and MBD4 are effectively competed
away upon addition of 100-fold excess unlabeled probe but not
upon addition of the same amount of the unmethylated version
of this probe (Fig. 4, compare lanes 5 and 6, 9 and 10, and 17
and 18). While MBD3 forms a complex with the methylated
probe and not the unmethylated probe (Fig. 4, lanes 11 and
12), this shift is not competed with either methylated or un-
methylated probe (lanes 13 and 14) and thus is not a specific
shift. Both MBD1 and MBD2 are capable of binding to a probe
containing two symmetrically methylated CpGs located 25 bp
apart, though MBD4 failed to bind this probe (NB-HH probe
[Table 1]). MBD1, MBD2, and MBD4 all were capable of
specifically binding a probe containing one symmetrically
methylated CpG (MM2 [Table 1]). Additionally, MBD1 and
MBD4 binding can be competed by 100-fold excess hemim-
ethylated oligonucleotide [(GAM)12/(GTC)12] though signifi-
cantly less well than with a symmetrically methylated version of
the same probe (data not shown). The MBD2 shift is not
affected by this hemimethylated oligonucleotide. None of these
proteins bind single-stranded DNA whether methylated or not,
and they do not bind a double-stranded oligonucleotide con-
taining repeats of the sequence TpG (thymine being similar to
5-methylcytosine in that both are pyrimidines with a methyl
group at position 5). Thus MBD1, MBD2, and MBD4 proteins
specifically bind methylated DNA in vitro and preferably dou-
ble-stranded, symmetrically methylated DNA, although MBD1
and MBD4 complexes are also competed to a lesser extent by
hemimethylated oligonucleotides. The binding of MBD1, -2,
and -4 to methyl-CpGs appears to be independent of sequence
context in that they bind methylated versions of a number of
different oligonucleotide probes (Table 1).
FIG. 3. Expression of MBD1 to MBD3. cDNAs corresponding to Mbd1 (A),
Mbd2 (B), and Mbd3 (C) were hybridized to Northern blots containing 10 mg of
total RNA per lane from various murine tissues and ES cells. Size markers (in
kilobases) are shown to the left of each blot. Blots were stripped and rehybrid-
ized to a probe corresponding to mouse ribosomal protein 26 cDNA (S26) to act
as an RNA loading control. Sk. Muscle, skeletal muscle.
FIG. 4. Binding of recombinant MBD proteins to methylated DNA in vitro.
One hundred picograms of radiolabeled, double-stranded GAC (lanes 1, 3, 7, 11,
and 15) or GAM12 (lanes 2, 4 to 6, 8 to 10, 12 to 14, and 16 to 18) DNA (Table
1) was incubated with recombinant MBD proteins in the presence (1) or ab-
sence (2) of 200 ng of unlabeled methylated or unmethylated competitor DNA
and then electrophoresed through a 2% agarose gel. The location of the free
probe is indicated, and protein-DNA interactions are evidenced as slower-mi-
grating DNA. Approximate amounts of recombinant protein used were as fol-
lows: MBD1, 20 ng; MBD2b, 10 ng; MBD3, 100 ng; MBD4, 100 ng. All proteins
form a slower-migrating complex with methylated probe but not with the un-
methylated probe. The shifts of MBD1, MBD2b, and MBD4 are prevented by
the presence of excess, unlabeled, methylated DNA during incubation (M1
Competitor), but not by the addition of excess unmethylated DNA (M2 Com-
petitor). The full-length MBD2 protein also produces a methyl-specific shift
(data not shown). The shift produced by MBD3 is competed by neither meth-
ylated nor unmethylated DNA and is therefore considered to be nonspecific.
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MBD1, -2, and -4 proteins are targeted to methylated DNA
in vivo. Approximately 50% of all 5-methylcytosine is concen-
trated in major satellite in murine cells; subsequently MeCP2
protein has been found to be concentrated at this repetitive
sequence (35). Mouse major satellite is organized in foci of
constitutive heterochromatin and corresponds to regions of the
nucleus that stain brightly with Hoechst 33258 and DAPI (31).
The specific localization of MeCP2 is no longer seen in cells
with ,5% of normal DNA methylation (25), demonstrating
that appropriate cellular localization is dependent upon DNA
methylation (35). Having shown that the MBD proteins spe-
cifically bind methylated DNA in vitro, we wanted to deter-
mine whether the cellular localization of the MBD proteins is
consistent with them binding methylated DNA in vivo. To do
this, we examined their localization in normal murine cells and
in cells lacking .95% of normal DNA methylation (Fig. 5A).
Constructs designed to express GFP-tagged versions of each of
the MBD proteins under the control of a cytomegalovirus
promoter were transfected into either wild-type or DNMT-
deficient ES cells. As is shown in Fig. 5 and 6, ectopically
expressed MBD proteins were predominantly nuclear in mu-
rine cells. Nuclear localization was also seen in human
(HT1080) and hamster (CHO) cells (data not shown). Over-
expressed MBD1-GFP, MBD2-GFP, and MBD4-GFP prefer-
entially localized to regions of the genome known to be highly
methylated, as evidenced by colocalization of protein signals
with DAPI-bright areas (Fig. 5B to D).
MBD1-GFP, MBD2-GFP, and MBD4-GFP all localized to
major satellite in transfected wild-type murine cells, consistent
with their ability to bind methylated DNA in band shift assays.
Whereas MBD1-GFP showed heterochromatic localization in
all transfected cells, in cells expressing low levels of MBD2-
GFP and MBD4-GFP, unlocalized nuclear staining was often
observed. This pattern was seen in somatic murine cells (pri-
mary mouse cells and L cells [data not shown]) as well as ES
cells. In order to determine whether MBD2-GFP and MBD4-
GFP localization was disrupted in DNMT-deficient ES cells,
the following screening protocol was used. Coverslips were
scanned under 320 magnification, and cells containing a visi-
ble amount of GFP signal at this level of magnification were
then analyzed under 3100 magnification and scored for sub-
nuclear localization. Using this selection criterion, 100% of
wild-type ES cells analyzed showed localization of MBD2-GFP
or MBD4-GFP signal with major satellite. In contrast, DNMT-
deficient ES cells expressing MBD2-GFP or MBD4-GFP dis-
played an overall nuclear localization of the GFP signal (Fig.
5C and D), indicating that the association of MBD2-GFP and
MBD4-GFP with major satellite is dependent upon DNA
methylation. MBD1-GFP localized to major satellite in all
wild-type murine cells analyzed, irrespective of the amount of
fluorescence seen. In DNMT-deficient ES cells, MBD1-GFP
localized to DAPI-bright regions in most, but not all, nuclei
(Fig. 5B). This is in stark contrast with the patterns seen for
MBD2-GFP and MBD3-GFP, as well as that reported for
MeCP2-LacZ which localized to major satellite in a minority of
DNMT-deficient ES cells (35). The possibility of contamina-
tion of the DNMT-deficient ES cell cultures by wild-type ES
cells was ruled out by verifying the undermethylation of the
DNMT-deficient ES cells by digestion of total DNA with the
methylation-sensitive restriction enzyme MaeII (Fig. 5A).
While normal ES cell DNA and somatic cell DNA is highly
resistant to MaeII digestion, the DNMT-deficient ES cell DNA
is readily digested with MaeII, which is able to digest the
sequence ACGT only when the cytosine is unmethylated (Fig.
5A, compare lane 2 to lanes 1 and 3). Blotting and probing of
this gel with major satellite DNA illustrate the high degree of
undermethylation of this repetitive sequence in the DNMT-
deficient ES cells compared to that of wild-type ES cells or








MBD1 MBD2 MBD3 MBD4
GAM12 12 GATCMGAMGAMGAMGAMGAMGAMGAMGAMGAMGAMGAMGATC 1 1 (1) 1 27
GAM5 5 CTAGAAMGAMGTGCMGAAGCTMGACCAGTGMGTGCTAG 1 1 (1) 1 27




















2 2 2 2 This study
Me51 3 GCCTTCAGMGCMGMGGATCCAGT 1 1 2 1 20
51 0 GCCTTCAGCGCCGCGGATCCAGT 2 2 2 2 20
MeSm 3 AGCAGCMGMGCCAAMGCTGGGAG 1 1 2 2 37a
Sm 0 AGCAGCCGCGCCAACGCTGGGAG 2 2 2 2 37a
MM2 1 TCAGATTCGCGCMGGCTGCGATAAGCT 1 1 2 1 This study
MM1 0 TCAGATTCGCGCCGGCTGCGATAAGCT 2 2 2 2 This study
a Sequence of one strand of double-stranded DNA probes used in gel shift assays. M, 5 methylcytosine. Methylated CpG dinucleotides are always methylated on both
strands.
b Binding of the protein to the DNA in band shift assays. Symbols: 1, binding; 2, no binding; (1), nonspecific binding. ND, not done.
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somatic cell DNA (Fig. 5A, compare lane 5 to lanes 4 and 6).
This observation may mean that the residual methylation
known to exist in the DNMT-deficient ES cells is sufficient to
direct MBD1-GFP to the major satellite. An alternate inter-
pretation of these results is that MBD1-GFP is tethered to
major satellite via some other protein factor and that this
association is independent of DNA methylation.
The MBD3-GFP fusion protein shows diffuse nuclear stain-
ing in low-expressing cells and accumulates in many nuclear
foci in cells expressing large amounts of the fusion protein.
These foci do not coincide with major satellite (Fig. 6). Thus,
MBD3 does not prefer to associate with the highly methylated
major satellite DNA in mouse cells. To determine whether the
failure of MBD3-GFP to localize to methylated DNA in vivo is
due to the presence of its acidic C-terminal tail, an MBD3
deletion protein (GFP-MBD3Nh [Fig. 6]), which is truncated
at amino acid 248, was expressed in murine cells. This protein
also localized to the nucleus in interphase mouse cells but was
excluded from the DAPI-bright regions, indicating that it is not
the acidic tail which is preventing GFP-MBD3 from associating
with methylated DNA in vivo. We next wanted to determine
whether the localization of MBD3 was influenced by its MBD-
like region. A version of MBD3 (GFP-MBD3Sp [Fig. 6]) lack-
ing amino acids 4 to 36 (the amino-terminal half of the MBD-
like region) and corresponding to the common alternately
spliced variant of Mbd3 message (Fig. 1B), was expressed as a
GFP fusion in murine cells. The localization of this deleted
MBD3-GFP protein was indistinguishable from that of the
full-length protein, leading us to conclude that the integrity of
the MBD-like region is not important for the localization seen
in this assay.
DISCUSSION
Searching the EST database with the amino acid sequence of
the MeCP2 MBD has revealed the presence of a family of
mammalian MBD-containing proteins. The absence of any
other known sequence motifs within MBD2 or MBD3 provides
no clues as to the activities of these two proteins. In contrast,
homology between MBD4 and bacterial DNA repair enzymes
is consistent with a DNA repair activity for MBD4 and may
indicate a link between DNA repair and methylation in mam-
mals, but this remains to be proven. Both the sequence and
genomic organization of the MBDs within each of the MBD
proteins makes it clear that these motifs are related evolution-
arily, but the lack of similarity between these proteins outside
FIG. 5. Binding of MBD proteins to methylated and hypomethylated genomes in vivo. (A) DNA from wild-type ES cells (lanes 1 and 4), DNMT mutant ES cells
(lanes 2 and 5), and murine somatic cells (lanes 3 and 6) was digested with the methylation-sensitive restriction enzyme MaeII (Boehringer Mannheim) and
electrophoresed on a 1% agarose gel. Lanes 1 to 3 show the ethidium bromide-stained gel, and lanes 4 to 6 show the gel blotted and probed with the 234-bp major
satellite repeat monomer. (B to D) Localization of MBD-GFP fusion proteins in nuclei of ES cells. Either wild-type (WT) or DNMT-deficient (DNMT2) ES cells were
transiently transfected with MBD1-GFP (B), MBD2-GFP (C), or MBD4-GFP (D) expression constructs. GFP fluorescence (upper panels) indicates the location of the
MBD-fusion protein. DNA is visualized in the same nuclei by DAPI staining (lower panels), and major satellite is visible as intense spots of DAPI fluorescence. All
fusion proteins are predominantly nuclear in all cells. MBD1-GFP colocalizes with major satellite in wild-type and mutant cells. MBD2-GFP and MBD4-GFP colocalize
with major satellite in wild-type ES cells but fail to localize to major satellite in DNMT-deficient ES cell nuclei. Localization of MBD4-GFP to the nucleolus in
DNMT-deficient ES cell nuclei was not observed consistently.
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of the MBD (excluding MBD2 and MBD3) may indicate that
each protein carries out a different function within the cell.
Both MeCP2 and MBD1 are capable of transcriptional re-
pression at methylated promoters (15, 32), though there is no
sequence in MBD1 (or any of the other MBD proteins) which
bears any recognizable sequence homology to the TRD of
MeCP2. The recent finding that MeCP2 TRD binds to the
Sin3-histone deacetylase complex (22, 34) provides an attrac-
tive molecular picture of the potential mechanism of action of
MeCP2: MeCP2 binds to methylated DNA via its MBD and
attracts the Sin3-histone deacetylase complex via its TRD,
resulting in the deacetylation of methylated chromatin and
subsequent transcriptional silencing. The absence of any TRD-
like sequence in MBD1 may mean that the mechanism by
which MBD1 represses transcription is different from that used
by MeCP2. Alternately MBD1 may use the same mechanism as
MeCP2 but contain a novel Sin3 binding domain or may bind
deacetylases directly.
All of the MBD proteins, including MeCP2, are ubiquitously
expressed in somatic tissues, but only Mbd3 and Mbd4 tran-
scripts are readily detectable in ES cells. Although ES cells
generally have highly methylated genomes, this methylation is
not necessary for viability (25). MeCP2 is very weakly ex-
pressed in ES cells and is also not needed for viability (42).
Thus, DNA methylation and the presence of MeCP2 do not
appear to be important in ES cells, and therefore, the finding
that Mbd1 and Mbd2 transcript levels are significantly reduced
in this cell type is not surprising. Mbd3 and Mbd4 are both well
expressed in ES cells, but whether the corresponding proteins
are present or important for ES cell viability is not known.
All of the MBD proteins except MBD3 bind to methylated
oligonucleotide probes in vitro but do not bind to the unmeth-
ylated versions of these oligonucleotides under our conditions.
Recently, the chicken homologue of MeCP2 was proposed to
be a component of the nuclear matrix and was shown to be
capable of binding to a TG-rich “matrix attachment region”
sequence in gel shift assays (45). Though low-affinity TG bind-
ing has been detected for rat MeCP2 in vitro (35a), we de-
tected no affinity of MBD1, MBD2, MBD3, or MBD4 for
TG-containing probes in gel shift assays (data not shown).
We have taken advantage of the fact that approximately half
of all 5-methylcytosine in mouse cells is located at the pericen-
tromeric heterochromatin (31) in order to investigate the abil-
ity of the MBD proteins to localize to methylated DNA in vivo.
Ectopically expressed GFP-fusions of MBD1, MBD2, and
MBD4 colocalized with major satellite in mouse cells, but
localization of MBD2 and MBD4 was disrupted in cells lacking
a functional DNMT gene (Fig. 5). This suggests that MBD2
and MBD4 are capable of binding methylated DNA in vivo as
well as in vitro. MBD1 is also capable of associating with
methylated DNA in vivo but binds to the same heterochro-
matic sites in DNMT-deficient ES cells. It is not clear whether
MBD1 is binding to low levels of DNA methylation in DNMT-
deficient cells or to some other heterochromatin binding pro-
tein. Similarly, we cannot formally rule out the possibility that
the localization of MBD2 and MBD4 to murine heterochro-
matin is due to their interaction with some other methylation-
sensitive heterochromatin binding protein. It is unlikely that
MeCP2 is responsible, as protein activity is undetectable in ES
cells (30) and localization of MBD1-, MBD2-, or MBD4-GFP
fusion proteins is not disrupted in MeCP2-deficient somatic
cells (17a).
MBD3 behaves differently than the other MBD proteins,
failing to specifically bind methylated DNA in vitro (Fig. 4C)
or colocalize with major satellite in vivo (Fig. 6). The difference
in specificity between the highly similar MBD2 and MBD3
proteins cannot be attributable to their divergent C termini, as
a truncated version of MBD3 which lacks the C-terminal 37
amino acids, including the glutamic acid repeat, also fails to
localize to DAPI-bright regions in mouse nuclei (Fig. 6). Nor
can it be attributable to the additional 150 amino acids N-
terminal to the MBD of MBD2, since a shorter MBD2-GFP
FIG. 6. Localization of GFP-MBD3 fusion proteins in nuclei of somatic cells. The mouse embryonic fibroblast cell line EFS2 was transiently transfected with
GFP-MBD3 fusion protein expression constructs. The top panels show GFP fluorescence, while the lower panels show DAPI staining of the same cells. The constructs
used are diagrammed at the bottom, with MBD depicted as a gray box and the glutamic acid repeat depicted as a black box. In all cases, GFP is located at the N
terminus. (A) The full-length MBD3 fusion protein localizes to the nucleus and occasionally forms bright foci of GFP fluorescence, but these spots do not correspond
to the major satellite. (B) Removal of the glutamic acid repeat (GFP-MBD3Nh) does not alter subnuclear localization, nor does removal of the N-terminal half of the
MBD (GFP-MBD3Sp [C]). A fourth construct in which GFP is located at the C terminus of full-length MBD3 showed a localization pattern indistinguishable from
that of GFP-MBD3 (data not shown).
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protein which lacks this region also localizes to major satellite
in murine cells (data not shown). Thus, the DNA binding
specificities are most likely attributable to differences in the
MBDs of the two proteins (Fig. 1A and 2). It is possible that
the MBD of MBD3 is nonfunctional, since a GFP fusion of an
MBD3 variant resulting from the product of the common al-
ternately spliced RNA species (Fig. 1B) which lacks the N-
terminal half of the MBD-like sequence shows an in vivo lo-
calization pattern indistinguishable from that of the full-length
protein (Fig. 6). Despite the high degree of sequence similarity
between MBD2 and MBD3, these two proteins display com-
pletely different DNA binding activities and in vivo localization
patterns. The very high degree of conservation between the
murine and human homologues of these two proteins (97.6%
amino acid identity for MBD2 and 93.8% for MBD3) indicates
that both proteins are functional. One possible explanation for
these observations is that Mbd3 arose by gene duplication of
Mbd2, but has acquired a novel DNA binding specificity which
our ectopic overexpression techniques have not detected.
Whether MBD2 and MBD3 perform similar functions despite
having different DNA binding abilities remains to be deter-
mined.
MeCP2 localizes to major satellite at a very low frequency in
DNMT-deficient cells (35). This may be attributable to the
nonspecific DNA binding activity of MeCP2 which, in the ab-
sence of methyl-CpGs, may allow it to bind to the TG-rich
major satellite (27). We have found no in vitro evidence that
any of the proteins described here has any sequence specificity
other than the absolute requirement for the presence of meth-
ylated CpGs. Nevertheless, there are hints of different binding
specificities in vivo. Whereas MBD1-GFP location is coinci-
dent with DAPI-bright regions in all transfected murine cells,
MBD2-GFP and MBD4-GFP fail to bind major satellite in
murine cells expressing very small amounts of the fusion pro-
tein (data not shown). This observation may indicate a DNA
binding preference of MBD2 and MBD4 for methylated eu-
chromatic sites over those found in major satellite. Similarly,
the different frequencies with which the MBD proteins are
found to localize to major satellite in ES cells lacking .95% of
normal methylation levels may reflect the density of methyl-
ation required in a given sequence for each protein to bind.
For example, MBD1 may be capable of binding to DNA con-
taining low methylation levels, MeCP2 may require a some-
what higher level of methylation, and MBD2 and MBD4 may
bind only heavily methylated DNA. This possibility will require
quantitative DNA binding assays to be tested rigorously.
DNA methylation is absolutely required for mammalian de-
velopment (29). The signal that DNA methylation represents is
interpreted by methylated DNA binding proteins, and until
now only two of these—MeCP2 and MBD1—had been defined
molecularly (15, 27). The identification of MBD2 and MBD4
as specific methyl-CpG binding proteins provides two more
candidates for proteins that mediate the effects of DNA meth-
ylation.
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